Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Tyrosine glycosylation of Rho by Yersinia toxin impairs blastomere cell behaviour in zebrafish embryos


Yersinia species cause zoonotic infections, including enterocolitis and plague. Here we studied Yersinia ruckeri antifeeding prophage 18 (Afp18), the toxin component of the phage tail-derived protein translocation system Afp, which causes enteric redmouth disease in salmonid fish species. Here we show that microinjection of the glycosyltransferase domain Afp18G into zebrafish embryos blocks cytokinesis, actin-dependent motility and cell blebbing, eventually abrogating gastrulation. In zebrafish ZF4 cells, Afp18G depolymerizes actin stress fibres by mono-O-GlcNAcylation of RhoA at tyrosine-34; thereby Afp18G inhibits RhoA activation by guanine nucleotide exchange factors, and blocks RhoA, but not Rac and Cdc42 downstream signalling. The crystal structure of tyrosine-GlcNAcylated RhoA reveals an open conformation of the effector loop distinct from recently described structures of GDP- or GTP-bound RhoA. Unravelling of the molecular mechanism of the toxin component Afp18 as glycosyltransferase opens new perspectives in studies of phage tail-derived protein translocation systems, which are preserved from archaea to human pathogenic prokaryotes.


Tight regulation of cytoskeletal organization and activity enables cells to assemble and function in an organism1, but the cytoskeleton is also a target of infectious agents causing severe pathologies. Bacterial virulence factors post-translationally modify key regulators of the cytoskeleton, like the family of Rho GTPases, to disseminate or evade host defense mechanisms2,3,4,5. The molecular identification of toxins selectively modifying regulatory components of the cytoskeleton can also be useful to uncover cellular processes, equally important for morphogenesis and disease pathogenesis6,7. Therefore, insights into virulence mechanisms of toxins, particular those modulating Rho GTPases, may promote the understanding of the control of cellular morphology, motility and cell division.

Rho GTPases control cell shape, polarity and motility by regulation of the actin cytoskeleton1,8,9. Accordingly, Rho GTPase signalling regulates germ cell migration in the embryo10, and epithelial-to-mesenchymal transition initiating neural crest cell migration11. Controlled by planar cell polarity signalling, RhoA and its effectors regulate convergence and extension movements of embryonic tissue during gastrulation12,13,14. Functions of specific Rho GTPases have been analysed during cancer progression15, as well as during pathogenic processes on bacterial infection16. The use of Rho-specific toxins17 and the discovery of pharmacological inhibitors18 of Rho signalling were essential to uncover developmental as well as disease-related mechanisms.

Several Yersinia species are highly pathogenic for humans and animals causing diseases as diverse as plague and enterocolitis. Y. ruckeri is the causative agent of enteric redmouth disease, a generalized septicaemia in salmonid fish species19. Despite the economic significance of the disease, very little is known about the pathogenesis and even less is reported on molecular virulence mechanisms. Virulence is presumed to be mediated by a phage-derived needle-like particle complex called antifeeding prophage (Afp)20, which shares key characteristics in common with type VI secretion systems (T6SS), R-type pyocins and the Photorhabdus luminescens virulence cassette PVC20,21,22. Variants of this gene cassette equip numerous prokaryotes including pathogenic Gram-negative and Gram-positive bacteria but also Archaea21,23. Similar to phage tail-like pyocins and type VI secretion systems (T6SS), Afps appear to consist of a contractile sheath, an inner tube, baseplate components and tail fibres, but are devoid of a phage head component (Fig. 1a)20,21. The genes Afp1–18 are assumed to encode an 100-nm contractile prophage tail structure that on stimulation contracts a sheath protein complex to eject the inner tube, which penetrates the eukaryotic prey cell20,23,24. Afp18 appears to be the toxin unit, the ‘warhead’, which is suggested to be enclosed in the core tube of the machinery and injected into eukaryotic host cells20. For Serratia entomophila, it was shown that Afp18 is responsible for a toxic antifeeding phenotype when introduced into insect hosts23.

Figure 1: Yersinia ruckeri antifeeding prophage tail (Afp) translocation system and effects of the glycosyltransferase domain of Afp18.

(a) Organization of Afp genes from Yersinia ruckeri and Serratia entomophila with their predicted and ascribed protein domains. The toxin units are shown in red. Bottom: pairwise genomic gene analysis of aligned Afp gene clusters using mVISTA ( Indicated is the average per cent of nucleotide identity within a window of 20 nucleotides. Nucleotide identity >70% is shaded in red. (b) Architecture of Y. ruckeri Afp18 and similarity to the virulence gene product Afp18 from S. entomophila. Amino-acid sequence alignment of the region surrounding the DxD motif (marked) of different toxin glycosyltransferases. Secondary structure elements are deduced from the crystal structure of PaTox (pdb code 4MIX). Accession numbers are the following: P. asymbiotica PaTox (PaGT, accession number C7BKP9), Legionella pneumophila glucosyltransferase 1 (Lgt1, accession number Q5ZVS2), Clostridium difficile toxin B (TcdB, accession number P18177), C. sordellii lethal toxin (TcsL, accession number Q46342), C. novyi α-toxin (TcnA, accession number Q46149). Alignment was prepared using ClustalW and rendered using ESPript 3.0 ( Identical residues are boxed and shown in red, similar residues are boxed in yellow. (c) Live images of non-injected, PBS buffer control, Afp18G NxN and Afp18G protein (each 3 μM, 1 nl injection) injected zebrafish embryos at indicated developmental stages, 16-cell (1.5 h.p.f.), 256-cell (2.5 h.p.f.) and 30% epiboly (4.7 h.p.f.). Arrows mark blastomere cleavage furrows at 16-cell and 256-cell, embryos are oriented animal to the top. At the 16-cell stage, Afp18G-injected embryo blastomeres show cleavage planes, while blastomeres fail to establish cell boundaries at the 256-cell stage. Control embryos at 30% epiboly develop normally compared with non-injected WT, while Afp18G-injected embryos show disrupted blastoderm (arrowhead) or disintegrate completely (asterisk). Scale bar, 200 μm.

To study the Afp18 virulence effector of Y. ruckeri, we employed the zebrafish embryo as a model, in which cell biological processes during vertebrate development can be visualized at high spatial and temporal resolution. The early cleavage, blastula and gastrula stages of zebrafish development are an excellent model to study individual and collective cellular behaviours25. Analyses of infection of zebrafish with Y. ruckeri and other pathogens have provided insights into disease mechanism6,26 as well as function of the innate immune system27,28.

Here we describe the molecular mechanism of the virulence gene product Afp18 from Y. ruckeri. Afp18 mediates toxicity via a glycosyltransferase domain that disrupts RhoA GTPase-dependent actin organization. We find that non-reversible glycosylation at a highly conserved tyrosine residue is responsible for the loss of RhoA activity. Tyrosine glycosylation results in a structural perturbation of the switch I region in RhoA. This inhibits the interaction of RhoA with regulators and downstream signalling effectors, resulting in disturbed actin regulation and abrogates early zebrafish development.


Afp18 gene harbours a putative glycosyltransferase domain

Y. ruckeri Afp18 is a component of the prophage tail-like injection machinery (Afp) and exhibits similarities with Serratia Afp18 in terms of size and amino-terminal architecture, but differs in the carboxyl-terminal toxic domain (Fig. 1a,b, scheme). The toxic domain of Yersinia Afp18 comprises a putative glycosyltransferase domain (Fig. 1b, green coloured region), which exhibits significant sequence similarity to glycosyltransferase toxins from Legionella pneumophila (Lgt1–3), Photorhabdus asymbiotica (PaTox) and clostridial glycosylating toxins, including toxin A and B from Clostridium difficile (Fig. 1b, sequence alignment)29. All these glycosyltransferases contain a conserved DxD-(aspartic acid- × -aspartic acid) motif, which is essential for sugar donor substrate binding and, thus, crucial for enzymatic activity. Mutations of this motif result in catalytic defective enzymes7,30,31.

Afp18G severely affects early zebrafish embryo development

To assess the cellular effects and toxicity of Afp18, we isolated the DNA and cloned the variable carboxyl-terminal fragment (Afp18G; amino acids 1,771–2,123) comprising the putative glycosyltransferase domain. In our studies, we used Y. ruckeri isolated from an infected rainbow trout in Idaho, USA. This strain is identical to Y. ruckeri recently isolated from a wound infection of a 16-year-old male patient in Belgium32. We purified the Afp18G protein in E. coli and microinjected the recombinant protein into zebrafish zygotes at one-cell stage. In addition, we constructed an Afp18G mutant with an exchange of the DxD motif against an enzymatically non-functional NxN, which we injected as control. Afp18G NxN injected embryos developed normally and were indistinguishable from non-injected or buffer injected control embryos (Fig. 1c). Afp18G-injected embryos performed the first three to four cell divisions with morphologically visible cleavage planes between the dividing blastomeres (Fig. 1c, 16-cell stage, arrows), albeit progress of development was delayed compared with controls. At the 256-cell stage, 2.5 h post fertilization (h.p.f.), control embryos showed normal development of the blastoderm positioned on top of the large vegetal yolk cell. In contrast, Afp18G-injected embryos failed to establish the typical multilayered organization of the blastoderm and large sections of the blastoderm were devoid of morphologically discernible cell boundaries (Fig. 1c, 256-cell stage, arrow). About 1 h later, at the onset of gastrulation, control embryos initiated epiboly, a coordinated cell movement, in which the static blastomeres became motile and spread vegetalward to cover the yolk cell. In contrast, Afp18G-injected embryo did not initiate epiboly, the blastoderm disrupted and in most severe cases the yolk cell and (or) blastomeres lysed and embryos completely disintegrated (Fig. 1c, 30% epiboly, arrowhead and asterisk, respectively). These data reveal that the glycosyltransferase domain of Afp18 is crucial for its severe toxic effect on early zebrafish development.

Dose-dependent effects of Afp18G on embryo development

To rule out contribution of effects by contaminants from the E. coli-derived protein preparation, we microinjected mRNA encoding the Afp18G protein. Dilution series of Afp18G encoding mRNA facilitated to determine effects of a wider range of toxin dosage. We injected 0.1–100 pg in vitro transcribed Afp18G or Afp18G NxN mRNA per embryo, or as control GFP mRNA. Morphological phenotypes were documented at the 1,000-cell stage (3.3 h.p.f.; Fig. 2a,b quantitative analysis; Supplementary Fig. 1). Embryos injected with 0.1 pg Afp18G mRNA did not develop significantly different from control embryos. About 30% of the embryos injected with 0.5 pg Afp18G mRNA developed a disintegrated blastoderm, with irregular cell shape, local loss of blastomere boundaries and abnormal cell sizes (arrowhead in Fig. 2c, 0.5 pg). Injection of 1 pg Afp18G mRNA per embryo affected cell morphology in all analysed embryos. Frequently, larger cells detached from the blastoderm and abnormal vesicles were formed (arrowhead in Fig. 2c). When 10 or 100 pg Afp18G mRNA were injected per embryo, cell morphology was severely affected, tissue integrity progressively lost during gastrulation and blastoderms frequently disintegrated (Fig. 2c and Supplementary Fig. 1a). In contrast, microinjection of mRNA encoding the glycosyltransferase-deficient mutant Afp18G NxN had no effect on embryonic development, revealing that the effects were indeed caused by the glycosyltransferase activity. Given that the effects of Afp18G on cellular functions cannot be analysed when embryos disintegrate early, we chose to inject 0.5 pg Afp18G mRNA for further analyses.

Figure 2: Afp18G disturbs zebrafish early development.

(a) Live images of non-injected, GFP, Afp18G NxN mRNA (each 100 pg per embryo), or different amounts (0.1–100 pg per embryo) of Afp18G mRNA-injected embryos at 1,000-cell stage (3 h.p.f.). Embryos oriented animal to the top. Scale bar, 500 μm. (b) Quantification of the blastoderm phenotype of control and Afp18G-injected embryos shown in a at 1,000-cell (non-injected, n=41; GFP mRNA, n=37; Afp18G NxN mRNA, n=52; 0.1 pg Afp18G, n=35; 0.5 pg Afp18G, n=45; 1 pg Afp18G, n=60; 10 pg Afp18G, n=62; 100 pg Afp18G, n=60). Only values for 100 pg per embryo injected GFP and Afp18G NxN mRNA are shown. Developing live embryos were classified into categories ‘normal’ (WT like), ‘disrupted blastoderm’ (cellular structure of blastoderm abnormal) or ‘disintegrated embryos’ (blastoderm and (or) yolk cell lysed). The distribution of phenotypes was analysed for significant differences using Fisher exact probability test, revealing significant differences (*P values <0.0001) between Afp18G NxN control and Afp18G samples. (c) Optical image planes of live blastoderm regions at 1,000-cell (3 h.p.f.) of non-injected, GFP, Afp18G NxN or Afp18G mRNA-injected embryos (pg per embryo) oriented animal to the top. Control embryos show normal development of blastomeres, while the blastoderm progressively loses cellular integrity with increasing amounts of Afp18G mRNA injected. Arrowheads mark the disrupted regions without visible blastomere boundaries, abnormal sized and irregular shaped cells. Asterisks mark detached blastomeres and disintegrated blastoderm. Scale bar, 100 μm. (d) Live images of control, full-length Afp18 and full-length Afp18 NxN mRNA (each 50 pg per embryo) injected zebrafish embryos. Afp18-injected embryos disintegrate at 1,000-cell stage (3 h.p.f., upper row, embryos are oriented animal to the top) and degrade early in gastrulation (lower row 40% epiboly, 5 h.p.f.). Scale bar, 500 μm. For five different concentrations each of Afp18 (non-injected n=80; 2.5 pg n=34; 5 pg n=50; 12.5 pg n=65; 25 pg n=85; 50 pg n=38) and Afp18 NxN (2.5 pg n=43; 5 pg n=58; 12.5 pg n=50; 25 pg n=76; 50 pg n=23) mRNA injections, the bar graph shows percentage of embryos, which at 5 h.p.f. develop like WT controls or degrade.

The G domain is the major pathogenicity determinant in Afp18

Next we wanted to clarify whether parts of Afp18 other than the glycosyltransferase (G) domain affect zebrafish embryo development. Therefore, we injected mRNA encoding the full-length Afp18 protein, or the enzymatically non-functional Afp18 NxN mutant, and analysed embryos and early larvae to identify potential morphological alterations in embryogenesis. Full-length Afp18 caused severely degraded embryos during early gastrulation (40% epiboly; Fig. 2d), while Afp18 NxN injected embryos developed indistinguishably from non-injected wild-type (WT) control embryos (Fig. 2d). These data revealed that the glycosyltransferase domain is the Afp18 protein domain mediating toxicity in this assay.

Afp18G disrupts the actin cytoskeleton

To analyse the in vivo cellular components affected by the Afp18G toxin, we co-injected mRNAs encoding Lifeact-GFP (green fluorescent protein) to fluorescently label the actin cytoskeleton and histone H2B-dsRed to label nuclei in living embryos. On Afp18G mRNA injection, blastomeres were severely enlarged (Fig. 3a, asterisk). In addition, blastomeres frequently contained two or more nuclei. We assumed that these Afp18G-induced morphological alterations were caused by deregulation of F-actin cytoskeleton organization. The Lifeact-GFP signal suggested a reduced amount of polymerized actin in Afp18G-expressing embryonic cells (Fig. 3a, Supplementary Movie 1). To analyse the effects of Afp18G on the actin cytoskeleton in more detail, we introduced recombinant 6xHis-tagged glycosyltransferase domain protein into zebrafish ZF4 cells (embryo-derived fibroblast-like cell line)33, using protective antigen (PA; the binding and translocation component of anthrax toxin) as a delivery system34, and stained filamentous actin with TRITC-phalloidin. Cells to which the glycosyltransferase-deficient NxN-mutant was delivered (Fig. 3b, middle panel) had an actin cytoskeleton indistinguishable from untreated control cells. In contrast, cells to which Afp18G was delivered showed a massive loss of actin fibres (Fig. 3b, bottom right panel) and finally rounded up (Fig. 3b top right panel). Live imaging of ZF4 cells transfected with GFP-actin revealed a complete disassembly of the actin cytoskeleton after delivery of Afp18G (Fig. 3c, time series bottom row; top row Afp18G NxN-treated control cell). The actin-depolymerizing effect was remarkably rapid. During 60 min of incubation, actin fibres disappeared and ZF4 cells collapsed. Comparable effects were observed using human HeLa cells (Supplementary Fig. 3a). Thus, the glycosyltransferase activity of Afp18 appears to severely affect the regulation of cellular actin.

Figure 3: Afp18G affects the actin cytoskeleton.

(a) Live images of Afp18G NxN or Afp18G mRNA (each 0.5 pg per embryo) injected embryos at 30% epiboly. Embryos are co-injected with mRNA encoding Lifeact-GFP (green) and H2B-dsRed (magenta; 100 pg per embryo each) labelling the F-actin cytoskeleton and the nuclei. Afp18G NxN embryos developed indistinguishable from WT embryos. Differential interference contrast (DIC) images of blastomeres are shown in the upper row, the corresponding confocal epifluorescence images below. Asterisk marks abnormally large blastomere; the arrow marks a blastomere with two nuclei. Single-plane image, scale bar, 20 μm. (b) Fluorescent micrographs of ZF4 cells treated with 6xHis-tagged Afp18G (right panel) or glycosyltransferase-deficient mutant Afp18G NxN (middle panel) proteins in combination with anthrax protective antigen (PA) as translocation system for His-tagged proteins. Top row shows phase-contrast images. Bottom row shows TRITC-phalloidin staining (red) of the actin cytoskeleton and a DAPI nuclei staining (magenta) of ZF4 cells fixed after 2 h. Arrows indicate regular stress fibres of F-actin in Afp18G NxN cells compared with disrupted F-actin fibres in Afp18G treated cells. Scale bar, 50 μm (top panel), 10 μm (bottom panel). (c) Time-lapse microscopic images of GFP-actin expressing HeLa cells intoxicated with Afp18G NxN (top row) and Afp18G (bottom row) as described in b. Scale bar, 10 μm. DAPI, 4′,6-diamidino-2-phenylindole.

Afp18G affects cytokinesis in early development

We examined whether the completion step of cell division, involving coordinated actin rearrangement, was affected by Afp18. We found that cytokinesis proceeded normally in Afp18G NxN expressing control embryos (Fig. 4a, upper row, arrow; Supplementary Movie 1). In contrast, cytokinesis including the assembly of the actomyosin ring and formation of the cleavage furrow was severely impaired in blastomeres of Afp18G mRNA-injected embryos, resulting in cells frequently containing more than one nucleus (Fig. 4a, lower row, arrow; Supplementary Movie 1). We evaluated cortical and cytoplasmic deposition of F-actin via measurement of the integrated density of Lifeact-GFP fusion protein fluorescence (Fig. 4b). The ratio of cytoplasmic versus cortical F-actin localization at three developmental time points (sphere, 30% epiboly, 50% epiboly) was almost constant in blastomeres of Afp18G NxN control injected embryos, when measured in 30 min time windows. In contrast, cortical actin was significantly enriched in blastomeres of Afp18G mRNA-injected embryos, indicating a deregulation of the dynamic organization of the actin cytoskeleton. However, the cell cycle phases involving proper assembly and organization of microtubule-based mitotic spindle progressed normally. Time series of Lifeact-GFP and H2B-dsRed labelled embryos revealed the accurate composition of the metaphase, with the sister chromatids moved to the opposite spindle poles for both, Afp18G NxN (Fig. 4a, upper row) and Afp18G (Fig. 4a lower row) mRNA-injected embryos. In summary, Afp18G seemed to selectively affect actin-dependent filament organization and dynamics during cytokinesis, while microtubule dynamics and karyokinesis appeared to progress normally.

Figure 4: Afp18G blocks cytokinesis leading to multinucleated cells.

(a) Cytoskeleton and cytokinesis analysed by time series of Afp18G NxN (upper row) or Afp18G (lower row) mRNA (0.5 pg per embryo each) injected embryos at dome stage (4.3 h.p.f.). Embryos were co-injected with mRNA encoding Lifeact-GFP (green) and H2B-dsRed (magenta; 100 pg per embryo each) labelling the F-actin cytoskeleton and the nuclei. Asterisk marks dividing blastomeres. Afp18G NxN and Afp18G mRNA-injected blastomeres complete microtubule mediated mitotic phases including chromosome segregation. Arrows indicate the actin ring contraction during cytokinesis, which is strongly affected in Afp18G-dividing blastomeres. Confocal z-stack projection of 10-μm depth; scale bar, 10 μm. (b) Quantification of cytoplasmic versus cortical Lifeact-GFP integrated epifluorescence signal density at indicated developmental stages. Confocal image of Afp18G NxN (left side) and Afp18G (right side) injected embryo showing an example blastomere with manually defined areas of cortical (region depicted in between red and yellow selection) and cytoplasmic (region outlined by yellow selection) F-actin and analysed using Fiji-ImageJ software measure function (sphere, n=12 each; 30% epiboly n=12 each; 50% epiboly n=12 each). Scale bar, 10 μm. Values are average±s.e.m. Statistical significance was evaluated using Mann–Whitney test.

Bleb formation is impaired by Afp18G

The organization of the cortical actin network controls cell membrane protrusions, and, thus, has a strong influence on cell motility35,36. It was shown that spherical protrusions, called blebs, are formed dynamically at the membrane of migrating cells. We scored bleb formation of blastomeres of Afp18G and Afp18G NxN mRNA-injected embryos at the onset of epiboly. Fig. 5a and Supplementary Movie 2 show a time series of a forming bleb documented by differential interference contrast transmitted light (upper row, black arrowhead) and fluorescence microscopy of Lifeact-GFP (lower row, white arrowhead) of a control injected embryo (upper two rows). The three phases of a bleb life cycle—initiation (after 10 s), expansion (up to 30 s) and retraction (40 to 70 s)—were clearly visible. Initially, blebs form and grow devoid of actin, while during retraction fluorescently labelled Lifeact-GFP-actin signal appeared slightly enhanced. Blebbing was severely reduced in numbers but also in bleb size in Afp18G mRNA-injected embryos (Fig. 5a lower two rows), as quantified by bleb counts (Fig. 5a graph). In addition, we analysed other actin-driven protrusion behaviours of blastomeres, excluding blebbing. Time series of both Afp18G and Afp18G NxN mRNA-injected embryos showed blastomeres, which form lamellipodia driven by actin remodelling (marked by black and white arrows in differential interference contrast and fluorescence images, respectively; Fig. 5b and Supplementary Movie 2). Quantification revealed that blastomeres did not significantly differ in lamellipodia number (membrane protrusions with actin remodelling—see graph in Fig. 5b) when Afp18G and Afp18G NxN expressing embryos were compared.

Figure 5: Afp18G blocks cell blebbing without affecting lamellipodia and filopodia formation.

(a) Bleb formation analysed at 30% epiboly (4.7 h.p.f.) by time series of embryos injected with 0.5 pg per embryo of Afp18G NxN mRNA (upper two rows) or Afp18G mRNA (lower two rows). Embryos were co-injected with mRNA encoding Lifeact-GFP (100 pg per embryo) labelling the F-actin cytoskeleton. DIC images are shown in the upper row and corresponding epifluorescence images in the lower row. Black arrowheads indicate spherical membrane protrusions of a blastomere, known as bleb formation, which are initially devoid of actin (white arrowheads). In contrast, blastomeres of Afp18G-injected embryos show significantly less blebbing and blebs appear smaller. Graph shows the quantification of bleb formation of blastomeres in Afp18G mRNA compared with Afp18G NxN control injected embryos (0.5 pg per embryo) during a time series (frames: 10-s intervals for 300 s; Afp18G NxN n=75; Afp18G n=75 cells analysed of three different embryos, 25 blastomeres each). Values are average±s.e.m.; statistical significance was analysed using Mann–Whitney test. Scale bar, 10 μm. (b) Protrusive activity analysed in time series of Afp18G NxN (upper two rows) or Afp18G (lower two rows) mRNA (0.5 pg per embryo each) injected embryos at 30% (4.7 h.p.f.). Embryos were co-injected with mRNA encoding Lifeact-GFP (100 pg per embryo) labelling the F-actin cytoskeleton. DIC images are shown in rows 1 and 3 and corresponding fluorescent image in the rows 2 and 4. Both Afp18G NxN and Afp18G mRNA-injected embryos show blastomeres forming sheet-like membrane protrusions resembling lamellipodia, filled with actin bundles and actin branches (arrows). Scale bar, 10 μm. Quantification shows the percentage of analysed blastomeres forming blebs without actin, blastomeres forming sheet-like membrane protrusions with actin or blastomeres without membrane protrusion activity during the captured time series (Afp18G NxN n=41; Afp18G n=37 cells analysed from three different embryos). The statistical significance (P=0.0091) of differences between the proportion of Afp18G NxN and Afp18G blastomeres showing these specific behaviours was computed using the Kruskal–Wallis test. The analysis revealed that the distribution of cell behaviour types indeed differs significantly, caused by changes in blebbing activity but not in lamellipodia formation. DIC, differential interference contrast.

Blebs have been reported to be primarily controlled by RhoA and its effector ROCK-I37,38. In contrast, Rac and Cdc42, which increase actin-dependent lamellipodia formation, inhibit bleb formation and amoeboid migration39,40. Therefore, our in vivo data suggested that Afp18G predominantly targeted RhoA, whereas Rac1 and Cdc42 might be less affected. To determine whether Afp18 may co-localize with RhoA, we used DNA vector injection to generate mosaic embryos in which individual cells were expressing enzyme-deficient EGFP-tagged Afp18G NxN and RHOA. Anti-EGFP and anti-RHOA immunofluorescence revealed that EGFP-Afp18G NxN appeared to target the cell membrane, and evaluation of line scans of fluorescent profiles shows co-localization with RHOA (Supplementary Fig. 2).

Afp18G utilize UDP-N-acetylglucosamine to modify Rho GTPases

To identify the cellular targets of Afp18 in zebrafish, we elucidated the sugar donor for this reaction by enzyme-catalysed UDP-[14C]sugar hydrolysis and found that Afp18G efficiently hydrolysed UDP-[14C]GlcNAc (Fig. 6a). Using UDP-[14C]GlcNAc in a glycosylation reaction with Afp18G and cell lysate, we identified proteins with an electrophoretic mobility corresponding to 23 kDa, which were labelled with 14C-GlcNAc and migrated similarly to the GTPase RhoA (Fig. 6b). As Rho GTPases are known regulators of the actin cytoskeleton and putative substrate candidates, we applied RhoA, Rac1 and Cdc42 to an in vitro glycosylation reaction with 1 nM Afp18G and obtained a strong modification of RhoA. Signals of Rac1 and Cdc42 were hardly visible under these conditions (Fig. 6c). When we applied higher amounts of Afp18G (100 nM), we could also observe the glycosylation of RhoB, RhoC, Rac2 and Rac3, and Cdc42 (Supplementary Fig. 3b). Other subfamily members of the Rho family were not modified and also Ras proteins did not serve as substrates. Using mass spectrometric analysis of Afp18G glycosylated RhoA, Rac1 and Cdc42, we could confirm that these GTPases were modified by a single covalently attached N-acetylhexosamine (HexNAc) moiety, which resulted in a mass increase of 203 Da in the corresponding switch I peptides (Fig. 6d). Again, RhoA was modified most efficiently among these GTPases. Thus, RhoA may be the primary target of Afp18G and might explain the previous results obtained in RhoA-, Rac1- and Cdc42-mediated actin dynamic analysis in zebrafish embryos and ZF4 cells. To prove that the NxN mutant of Afp18 is inactive and not able to glycosylate RhoA, we used UDP-GlcNAz as donor in a click chemistry reaction with biotin alkyne and radiolabelled UDP-[14C]GlcNAc in a glycosylation reaction and show that the mutant indeed is deficient in glycosyltransferase activity (Fig. 6e). Furthermore, we analysed the nucleotide status of RhoA which is glycosylated by Afp18 and found that Afp18G preferentially modified GTP (GTPγS)-bound RhoA in comparison to GDP-bound or nucleotide-free RhoA (Supplementary Fig. 4a).

Figure 6: Afp18G selectively modifies RhoA using UDP-GlcNAc.

(a) Donor substrate specificity of Afp18G determined by UDP-glycosidase activity. Percentage of hydrolysed UDP-[14C]sugars was determined by PEI thin-layer chromatography and autoradiography after incubation for 10 min at 30 °C. Data are representative of three independent experiments. (b) Autoradiography of the SDS–PAGE from cell lysate incubated with Afp18G and indicated radiolabeled UDP-sugars. Western blot of RhoA (right panel) showed similar electrophoretic mobility as radiolabelled proteins. (c) Time course of in vitro GlcNAcylation of RhoA, Rac1 and Cdc42 by Afp18G (1 nM). Inserts show representative autoradiograms (upper panel) and Coomassie-stained SDS–PAGE (bottom panel). Error bars indicate s.e.m.’s of three technical replicates. (d) Extracted ion chromatograms of thermolysin-digested GST-RhoA, GST-Rac1 and Cdc42 treated with Afp18G (lower chromatogram) or untreated control (upper chromatogram). The molecular mass [M+2H]2+ of the switch I peptides (RhoA: 26SKDQFPEVYVPT37; Rac1: 24TTNAFPGEYIPT35; Cdc42: 24TTNKFPSEYVPT35) are indicated. Afp18G-modified GTPases (lower chromatogram) show a mass shift of 203 Da revealing a modification with a single N-acetylglucosamine (shifted blue curves). In comparison with Rac1 and Cdc42, RhoA was modified most efficiently. (e) The DxD motif of Afp18 is crucial for GlcNAcylation of RhoA. Recombinant RhoA was incubated in the presence UDP-GlcNAz or UDP-[14C]GlcNAc with Afp18G, Afp18G NxN or without toxin. Modified proteins were analysed by click chemistry using biotin alkyne and western blotting and autoradiography, respectively. Anti-RhoA served as input control.

GlcNAcylated RhoA is observed in an inhibited conformation

To identify the site of modification and gain insights into the structural alteration caused by GlcNAcylation of RhoA, we crystallized Afp18-modified RhoA in the presence of magnesium and GDP and solved the X-ray structure at 2.0 Å resolution (Fig. 7a, Table 1). In the RhoA structure, we could clearly assign additional electron density at the hydroxyl group of tyrosine-34 to an attached N-acetylglucosamine moiety (Fig. 7b, Supplementary Fig. 3c). Interestingly, despite the presence of magnesium in the crystallization conditions, the structure revealed an unusual GDP-bound but magnesium-free conformation. The overall fold of the crystal structure of GlcNAcylated RhoA is very similar to known structures of Rho GTPases. However, the switch regions, especially the switch I region, adopt a conformation with tyrosine-34 positioned away from the nucleotide binding pocket, resulting in a structure distinct from the structures of RhoA bound to GDP41 or GTP42, which is generally not compatible with effector and regulator interaction (Fig. 7c).

Figure 7: Structural consequences of RhoA GlcNAcylation at tyrosine-34.

(a) Crystal structure of glycosylated RhoA at tyrosine-34. Switch I and switch II regions are highlighted in blue. GDP is shown as sticks and balls in black. The GlcNAc moiety attached to tyrosine-34 is shown as sticks and balls in yellow. (b) Electron density map of a section of 2Fo−Fc protein (grey), contoured at a level of 1σ, showing GlcNAc moiety attached to tyrosine-34 of RhoA in the alpha configuration of the glycosidic bond (marked). Additional residues of the switch I region were omitted for clarity. (c) Superposition of the effector loops of GlcNAcylated RhoA with structures of non-glycosylated active GTPγS-bound RhoA (pdb code 1A2B)42 and inactive GDP-bound RhoA (pdb code 1FTN)41. The switch I and II regions of GlcNAc-modified RhoA adopt distinct open conformations. (d) Autoradiograms and Coomassie stainings of Afp18G-catalysed in vitro14C-GlcNAcylation of WT GST-RhoA and the indicated mutants. (e) Cytoplasmic OGA is unable to revert GlcNAcylation of Rho. RhoA was radioactively preglycosylated by Afp18G and applied to a deglycosylation reaction with GST-OGA. TAB1, preglycosylated by OGT, served as positive control. Autoradiographs (top panels) of 14C-GlcNAcylated RhoA and GlcNAcylated TAB1 are shown. Coomassie staining of RhoA, TAB1 and GST-OGA are shown as input controls.

Table 1 Data collection, phasing and refinement statistics for RhoAY34(GlcNAc).

Tyrosine-34 is located within the effector loop region conserved in all Rho family GTPases. In in vitro glycosylation experiments with Afp18, followed by tandem mass spectrometric (LC–MS–MS) analyses, we confirmed that also Cdc42 was GlcNAcylated at tyrosine-32 (Supplementary Fig. 3d). Furthermore, site-directed mutagenesis and in vitro glycosylation experiments with Y32(34)F mutants of RhoA, Rac1 and Cdc42 confirmed switch I tyrosine-32(34) as the acceptor site of modification (Fig. 7d, Supplementary Fig. 3e). No other hydroxyl-containing amino acid (threonine or serine) or recently discovered glycosyl acceptor residues as tryptophan43 or arginine44,45 were able to substitute tyrosine in RhoA as an acceptor residue for glycosylation (Fig. 7d).

Afp18 forms deglycosylation-resistant α-glycosidic bonds

The defined electron density of the sugar attached to the hydroxyl group of tyrosine-34 revealed the α-anomeric configuration of the glycosidic bond (Fig. 7b). This finding implies that the glycosylation mechanism proceeds under retention of the stereochemistry of D-α-GlcNAc. Thus, Afp18 can be grouped into the family of retaining glycosyltransferases. The stereochemistry of the glycosidic bond has most likely no influence on the functional consequences of Afp18-mediated glycosylation, but might have an influence on the stability of the glycoside inside the host cytoplasm. Only one enzyme, namely O-GlcNAcase (OGA) exists in eukaryotic cytoplasm, which is able to remove mono-O-GlcNAc moieties from proteins. OGA predominantly cleaves sugars attached in the β-configuration. To clarify whether the glycosidic bond on RhoA was resistant to hydrolysis of OGA, we tested 14C-GlcNAcylated RhoA in a deglycosylation reaction. As a control protein, we used TGF-beta-activated kinase 1 (TAB1) preglycosylated by nucleocytoplasmatic O-GlcNAc transferase (OGT), which was efficiently deglycosylated by OGA (Fig. 7e). Notably, OGA did not deglycosylate Afp18-modified RhoA. We confirmed these results by using CpNagJ, another highly efficient mono-O-GlcNAcase from Clostridium perfringens (Supplementary Fig. 3f,g). Taken together, we found that Afp18 is a mono-O-glycosyltransferase, which selectively uses UDP-GlcNAc as sugar donor substrate to modify Rho GTPases site-specifically at a switch I tyrosine residue.

RhoA GlcNAcylation blocks regulator and effector interaction

To elucidate the molecular consequences of tyrosine-34 GlcNAcylation of RhoA, we analysed the nucleotide binding and nucleotide exchange of RhoA by mant-GDP fluorescence spectroscopy. Whereas the Afp18-catalysed glycosylation of RhoA did not affect nucleotide binding kinetics of mant-GDP or mant-GppNHp, a non-hydrolysable GTP analogue, (Fig. 8a), RhoA modification blocked leukaemia-associated RhoGEF (LARG)-catalysed nucleotide exchange (Fig. 8b). This effect was not caused by competition of Afp18G with GEF (Supplementary Fig. 4b), because GEF-stimulated nucleotide exchange was only blocked by the addition of UDP-GlcNAc. Thus, RhoA GlcNAcylation by Afp18 prevented the activation step of the GTPase. In addition, the interaction of RhoA to its GTPase-activating protein p50RhoGAP was impaired by Afp18G-mediated glycosylation of tyrosine-34 (Supplementary Fig. 4c).

Figure 8: Functional consequences of tyrosine-34 glyosylation of RhoA.

(a) GlcNAcylation of RhoA by Afp18G does not alter nucleotide binding. Fluorimetric analysis of mant-GDP (mGDP) or mant-GppNHp (mGppNHp) binding to WT RhoA or glycosylated RhoA (RhoA-GlcNAc) bound to GDP. Nucleotide exchange was monitored by the increase in fluorescence on mant-nucleotide binding to RhoA. Data are representative of two independent experiments. (b) Nucleotide exchange was measured by mant-GppNHp exchange with WT RhoA, Afp18G-GlcNAcylated RhoA in the presence or absence of LARG. Data are represented as means±s.d. of three technical replicates. (c) Western blot analysis of RhoA, Rac1, Cdc42 pull-down experiments with zebrafish (ZF4) cells treated with Afp18G (plus PA for delivery), Afp18G NxN (plus PA for delivery) and C. difficile toxin B (TcdB). After Rho GTPase activation with CNF1, active RhoA was pulled down with ROCK II-coupled beads and Rac1 and Cdc42 with PAK-coupled beads. Bound GTPases were detected by western blotting using anti-RhoA, anti-Rac1, and anti-Cdc42 antibodies, respectively. Immunoblot of total RhoA is the loading control. (d) Live images at 30% epiboly (4.7 h.p.f.) of control non-injected, GFP mRNA (50 pg per embryo), RHOA mRNA (50 pg per embryo), RHOA Y34F (50 pg per embryo)+Afp18G mRNA (0.5 pg per embryo), Afp18G mRNA (0.5 pg per embryo)+RHOA mRNA (50 pg per embryo) or Afp18G (0.5 pg per embryo)+RHOA Y34F mRNA (50 pg per embryo) injected embryos. GFP mRNA (50 pg per embryo) was also included in each injection mix, and GFP fluorescence used to examine for homogenous expression: panels show transmitted light images in left columns and corresponding GFP fluorescence images in right columns. GFP, RHOA and RHOA Y34F injected embryos developed indistinguishable from non-injected control embryos. Scale bar, 500 μm. (e) Quantification of percentage embryos that develop normally or were severely affected regarding the organization of the blastoderm in experiment shown in d. Co-injection of RHOA or RHOA Y34F mRNA together with Afp18G mRNA significantly reduces the fraction of disrupted and degraded blastoderm phenotypes, and increases the fraction of embryos developing normally at 30% epiboly. Values are average mean±s.e.m. of four biological replicates. Significance (P values <0.001) of changes in phenotype distribution was valuated using the Kruskal–Wallis test.

Next, we analysed the interaction of Rho, Rac1 and Cdc42 with its downstream effectors Rho kinase α (ROCKII)- and p21-associated kinase (PAK) and used zebrafish (ZF4) cells in an effector pull-down assay using ROCKII- and PAK-coupled beads (Fig. 8c). To activate Rho GTPases independently of intracellular GEFs, we pretreated cells with cytotoxic necrotizing factor 1 (CNF1), a toxin that activates Rho GTPases constitutively by deamidation46. Subsequent cell intoxication with Afp18G totally blocked RhoA interaction with ROCKII, whereas RhoA could efficiently be precipitated from cells treated with the glycosyltransferase-deficient mutant Afp18G NxN. Toxin B from Clostridium difficile (TcdB), which glycosylates threonine-37 in RhoA and thereby inhibits Rho effector interaction, served as a control. Impaired effector interaction catalysed by Afp18G was also observed for Rhotekin, an effector of RhoA, in human HeLa cells (Supplementary Fig. 4d). Intriguingly, the interaction of Rac1 or Cdc42 with their effector PAK could not be blocked by Afp18-mediated GlcNAcylation, whereas TcdB treatment of ZF4 cells efficiently prevented PAK interaction (Fig. 8c). This is consistent with our findings in time-lapse microscopy of Afp18-intoxicated ZF4 cells, which showed a rapid degradation of filamentous stress fibres but a persistence of membrane dynamics like membrane ruffling and filopodia formation, which are regulated by Rac1 and Cdc42, respectively (Fig. 3c, Supplementary Movie 3). It seems that Afp18 specifically inactivates RhoA signalling, but less signalling of Rac or Cdc42.

Afp18G-phenotype suppression by RhoA overexpression

To determine whether Afp18G predominantly acts through the glycosylation of RhoA in vivo, we tried to rescue the toxin phenotype by co-injection of mRNA encoding human WT RHOA or the non-glycosylatable mutant version RHOA Y34F. Zebrafish RhoA as well as other Rho GTPases share over 95% sequence conservation with their human homologues16. Embryos injected with human RHOA or RHOA Y34F mRNA (up to 50 pg per embryo) alone developed normal, indistinguishable from non-injected or GFP mRNA-injected control embryos (Supplementary Fig. 5a). We co-injected RHOA or RHOA Y34F mRNA with 0.5 pg Afp18G mRNA and found the disrupted blastoderm phenotype rescued to a large extent, with more embryos developing normally compared with Afp18G mRNA-injected embryos (Fig. 8d and quantification Fig. 8e). Taken together, both human RHOA and RHOA Y34F overexpression were able to rescue development of early embryos from Afp18G toxicity.


Here we unravelled the mode of action of the toxic effector Afp18 of the prophage tail-like protein translocation machinery Afp from Y. ruckeri, which is the causative agent of enteric redmouth disease in salmonid fish species. We employed Afp18 for studies in zebrafish embryos, which have been shown to be a highly sensitive fish model for effector and toxin analyses26,27,28,47.

We observed that microinjection or expression of Afp18 in zebrafish early embryos abrogated development, and embryos died before gastrulation was completed. The glycosyltransferase-deficient mutant (Afp18 NxN) showed no developmental defects unravelling the glycosyltransferase domain as a major toxic determinant. Even at low expression of the glycosyltransferase domain Afp18G alone (0.1 pg Afp18G mRNA), cytokinesis was severely affected and multinucleated cells were formed. While microtubule-dependent processes like karyokinesis, including metaphase formation and chromatid segregation, progressed normally, actin filament dependent processes (for example, cytokinesis) were blocked. This finding became even more obvious by cell behaviour defects observed during gastrulation, when cells become motile. Afp18G-expressing blastomeres contained significantly less cytoplasmic filamentous actin compared with controls.

Notably, the Yersinia effector-expressing blastomeres had severely reduced blebbing activity. Membrane blebbing depends on actomyosin and is essential for amoeboid cell migration37,38,39,48. Accordingly, the combined reduction of blebbing and protrusive activity effectively blocked cell movements and progress of gastrulation, and finally abrogated embryo development. Deduced from the specific effects of Afp18 on the actin cytoskeleton (for example, inhibition of blebbing), we proposed that the observed defects of zebrafish embryo development depend on an action of Afp18G on the GTP-binding protein RhoA. This hypothesis was supported by numerous previous reports, showing that RhoA and its effector ROCK are essential for bleb formation and for amoeboid migration37,38. Notably, Rac and Cdc42, which are also master regulators of the actin cytoskeleton and crucially involved in control of lamellipodia-dependent mesenchymal migration, were shown to inhibit bleb formation and amoeboid migration in various model systems39,40. Moreover, a discrete pool of active RhoA is reportedly essential for the local assembly of the contractile actomyosin ring and for cytokinesis49. In contrast, in numerous studies, it was shown that RhoB, RhoC, Rac1 and Cdc42 are not essential and dispensable for cytokinesis49,50,51,52. Moreover, our finding that the overexpression of human RhoA and the non-glycosylatable mutant RhoA Y34F resulted in the suppression of the toxic phenotype was in line with the view that RhoA plays a predominant role in Afp18-induced developmental defects. This hypothesis was strongly supported by the finding that the effector protein Afp18 directly targets RhoA by GlcNAcylation.

We determined the crystal structure of Afp18-GlcNAcylated RhoA and identified the covalent sugar modification at tyrosine-34. RhoA modified at this site revealed an opened switch I region, distinct from structures of RhoA bound to GDP41 or GTP42. It was shown that the switch I region of RhoA and especially tyrosine-34 is located in the interface of functional complexes of RhoA and its GEFs or its effectors53. We assume that steric constraints of the attached GlcNAc-residue results in the distorted conformation, which is incompatible with regulator and effector interaction. This assumption was underlined by the finding that the RhoGEF LARG, p50RhoGAP and the effectors ROCK and Rhotekin were unable to interact with Afp18-modified RhoA. Further experiments revealed that higher concentrations of Afp18 also GlcNAcylated Cdc42 and Rac in vitro. The modification of tyrosine-32 was verified by impaired glycosylation of site-directed mutants and in the case of Cdc42 by mass spectrometric analysis. Remarkably, we found that after the expression of Afp18 in target cells, which blocked RhoA functions and inhibited the interaction of the GTPase with its effectors, Rac1 and Cdc42 were still able to interact with their effector PAK. This suggests that in vivo Afp18 is specific for RhoA, a finding which is in agreement with our results on the toxic effects of Afp18 in zebrafish embryos and the time-resolved morphological effects on the actin cytoskeleton in zebrafish (ZF4) cells. However, the overexpression of RhoA or the non-glycosylatable mutant RhoA Y34F did not totally rescue Afp18-dependent developmental defects. Therefore, we cannot entirely exclude that Afp18G modulates other Rho GTPases in vivo as well, which then may contribute to the developmental phenotype.

GlcNAcylation of tyrosine-34(32) of Rho GTPases was recently reported for PaTox, an exotoxin from entomopathogenic Photorhabdus asymbiotica7. In this study, PaTox-induced modification of RhoA was analysed by 1H-NMR spectroscopy. Our crystallization data extend these findings and show a conformation of the switch I region, which was not obvious from NMR data. Interestingly, both enzymes Afp18 and PaTox modify preferentially the active GTP-bound state of GTPases. While PaTox harbours an additional deamidase domain that deamidates heterotrimeric G proteins and is suggested to be involved in Rho activation, Afp18 possesses no typical deamidation domain. It remains to be clarified whether and how Afp18 causes activation of RhoA. Tyrosine-32(34) in Rho GTPases is also known to be modified by phosphorylation54,55, nitration56 and adenylylation (AMPylation)57 indicating a pivotal role of this residue in the endogenous regulation of Rho GTPase signalling. In contrast to well-known modifications of serine or threonine residues, glycosylation of a tyrosine residue has not been described in mechanistic detail.

Recently, several novel mono-O-glycosyltransferases were identified, which perform unusual amino-acid modifications in proteins, targeting arginine44,45, tryptophan43 and tyrosine7. Most of these enzymes derive from bacterial species and function as highly active bacterial toxins or effectors in eukaryotes. Site-directed mutagenesis of tyrosine-34 of RhoA to serine, threonine, tryptophan and arginine inhibited modification by the Yersinia glycosyltransferase showing that Afp18 is highly specific and accepts only tyrosine as an acceptor amino acid. Moreover, we analysed the stability of the covalent attached sugar by an in vitro deglycosylation assay with OGA that is the only known O-GlcNAcase in the eukaryotic host cytoplasm. In agreement with the crystal structure obtained, showing that GlcNAc is linked to RhoA in an α-anomeric configuration, OGA, which specifically cleaves β-glycosidic GlcNAc moieties, was not able to remove the sugar from RhoA. Thus, eukaryotic host cells seem not to be able to cope and revert these unusual post-translational modifications making Afp18 a highly efficient toxin and consequently, resistance against Yersinia Afp might not be possible by simply upregulating OGA expression in the prey cell.

Our knowledge about Afp prophage tail-like translocation machineries is still in its infancy. Recently, the Afp translocation apparatus of Serratia entomophila, the closest orthologue of the Yersinia Afp, has been described and first structural insights were obtained by negative stain electron tomography20,23. Afp from Y. ruckeri contains all genes required to build the contractile prophage tail injection apparatus and harbours the toxin effector Afp18, which is suggested to be caged inside the tail tube and injected into host cell cytoplasm23. Remarkably, from genome sequence analyses, a broad distribution of this system in prokaryotes including archaea has been proposed21. Afp-related systems are the Photorhabdus luminescens virulence cassette PVC and the phage tail-like R-type pyocins (also called bacteriocins), which share similarity with the type VI secretion system (T6SS). Effector proteins of phage tail-derived secretion systems have diverse functions both in competition with other prokaryote predators (antibactericidal activity) and in interaction with eukaryotic host cells. In contrast to common type VI secretion systems, the Afp system is probably released as preformed injection ‘torpedos’ and is not associated to the bacterial donor cell20,58. Thereby, the system is extremely efficient; only 500 particles of S. entomophila Afp have been reported to kill the New Zealand grass grub (Costelytra zealandica) host23. Recent studies unravelled the mode of action of several T6SS effectors59,60,61,62. However, to date, the molecular mechanism of Afp effectors remained enigmatic. Thus, our findings that Y. ruckeri Afp18 harbours a glycosyltransferase, is the first report on a phage tail-derived pyocin effector targeting a specific regulatory protein (Rho GTPases) in the vertebrate host cell and might also contribute to human disease32. The results of our study on the effector component Afp18 might serve as a paragon for the fast growing number of phage-like pyocin producing pathogenic bacteria.


Materials and bacterial strains

DNA-modifying enzymes were obtained from Fermentas (St Leon-Rot, Germany), Phusion High-Fidelity DNA Polymerase from New England Biolabs (Ipswich, MA) and PfuUltra HF DNA Polymerase from Stratagene (Waldbronn, Germany). UDP-[14C]glucose and UDP-[14C]N-acetylglucosamine were from Biotrend (Cologne, Germany). UDP-[14C]galactose was from Perkin-Elmer Life Sciences (Rodgau, Germany). 2′(3′)-O-(N-methylanthraniloyl)-guanosine 5′-diphosphate (mant-GDP) and mant-guanosine 5′-[β, γ-imido]triphosphate (mant-GppNHp) were from Jena Bioscience (Jena, Germany). pET-28a vector was from Novagen (Madison, WI), pGEX4T1 and pGEX-4T3 were from GE Healthcare (Freiburg, Germany). Yersinia ruckeri (ATCC 29473) was from the German Collection of Microorganisms and Cell Cultures (DSMZ) and cultivated in CASO bouillon at 28 °C. E. coli TG1 was used for general cloning and protein expression of pGEX constructs. E. coli BL21 (DE3) CodonPlus (Stratagene) were used for protein expression of pET constructs. Toxin B was prepared from Clostridium difficile supernatants and purified by anion exchange chromatography63. The plasmids pGEX4T1-LARG (766–1,138) was kindly provided by Mohammad Reza Ahmadian (University Düsseldorf, Germany). All other reagents were of analytical grade and purchased from commercial sources. For all proteins used in this study the accession numbers and the species are listed in Supplementary Table 2.


Anti-RhoA (3L74, dilution 1:500), anti-Cdc42 (Cat. No. 17–299, dilution 1:500), anti-Rac1 (23A8, dilution 1:2,500) and anti-GAPDH (6C5, dilution 1:20,000) antibodies were from Millipore (Schwalbach, Germany), anti-GFP (A10262, dilution 1:500), anti-chicken Alexa Fluor 488 (A11039, dilution 1:1,000), anti-rabbit Alexa Fluor 555 (A21430, dilution 1:1,000) antibodies were from Life Technologies (Darmstadt, Germany), and Horseradish peroxidase (HRP)-conjugated anti-MBP (Cat. No. E8038, dilution 1:5,000) was from New England Biolabs. Anti-GST (Cat. No. 27-4577-01, dilution 1:2,000) was from GE Healthcare, HRP-linked anti-mouse antibody from Rockland Immunochemicals (Limerick, PA) and HRP-conjugated anti-rabbit antibody from New England Biolabs.

Cloning of genes for bacterial and zebrafish expression

The gene Afp18 (C4ULG3) and the fragments Afp18G were amplified with Phusion DNA polymerase from the genomic DNA of Y. ruckeri (ATCC 29473) with oligonucleotide primers with additional restriction sites for BamHI and SalI (Supplementary Table 1). The genes were ligated into a predigested pET-28a vector with an introduced tobacco etch virus (TEV) protease cleavage site. QuikChange Kit (Stratagene, La Jolla, CA) in combination with PfuUltra HF DNA polymerase was used for the replacement of one to three nucleotides using the oligonucleotides shown in Supplementary Table 1. All sequences of corresponding plasmids were confirmed by sequencing (GATC Inc., Konstanz, Germany).

Recombinant protein expression

Escherichia coli BL21* CodonPlus cells (Stratagene) transformed with the desired plasmid were grown in LB broth supplemented with the corresponding antibiotics on a shaker at 37 °C until A600=0.8. Protein expression from the pET28-based plasmids was induced by 1 mM isopropyl-β-D-thiogalactopyranoside (Roth, Karlsruhe, Germany) for 4–5 h at 22 °C, and pGEX-based expression was induced with 0.2 mM isopropyl-β-D-thiogalactopyranoside at 37 °C for 6 h. Bacterial cells were harvested by centrifugation at 6,000g for 15 min, resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 25 mM imidazole, 30 μg ml−1 DNase I, 1 mM β-mercaptoethanol and 1 mM phenylmethanesulfonylfluoride) and lysed by French press or ultra-sonic treatment. In the case of RhoA purification, 100 μM GDP was added to the lysis buffer. The cleared lysate was subjected to chromatography on a glutathione-Sepharose or nickel-equilibrated chelating Sepharose Fast Flow column, according to the manufacturer’s instructions (GE Healthcare). Bound proteins were eluted with 10 mM reduced glutathione, 0.5 M imidazole, thrombin treatment or TEV protease treatment, depending on the construct used. Thrombin was removed by binding to benzamidine-Sepharose (GE Healthcare) and His-TEV by Ni2+-affinity chromatography. Further purification and removal of protein impurities or small molecular weight components as reduced glutathione, EDTA, labelled and unlabelled nucleotides or analogues was achieved by size-exclusion chromatography using Superdex 75 or Superdex 200 (each 10/300) columns. For crystallization, RhoA (amino acids 1–181) was expressed and purified as GST-tagged protein. After the removal of GST by thrombin treatment, RhoA was additionally purified by size-exclusion chromatography (Superdex 200, GE Healthcare).

Cell culture

HeLa cells (ATCC CCL-2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS), 1% non-essential amino acids, 4 mM penicillin, 4 mM streptomycin and 1% sodium pyruvate (Biochrom, Berlin, Germany). Cells were cultivated in a humidified atmosphere of 5% CO2 at 37 °C. Where necessary, the cells were starved overnight in DMEM without FCS. Danio rerio (ZF4) cells (ATCC CRL-2050) were cultivated in DMEM/F12 (Biochrom, Berlin, Germany) with 10% FCS, 4 mM penicillin, 4 mM streptomycin and Fungizone (Life Technologies) in 4% CO2 atmosphere at 28 °C. For intoxication of cells, GST-CNF1 (400 ng ml−1), native full-length C. difficile toxin B (TcdB, 1 ng ml−1) was applied into the medium or a combination of B. anthracis protective antigen (PA, 0.5 μg ml−1) and Afp18-fragments (370 ng ml−1) and incubated for 4 h if not otherwise stated. Transfection of cells was performed with peqFECT DNA (peqlab, Erlangen, Germany) as mentioned in the manufacturer instructions.

Actin staining

ZF4 or HeLa cells grown on glass coverslips were washed with PBS, fixed with 4% formaldehyde in PBS and permeabilized with 0.15% (v/v) Triton X-100 in PBS for 10 min at room temperature. Subsequently, the cells were incubated with TRITC-conjugated phalloidin and washed again with PBS. Cells were embedded with Mowiol supplemented with 1,4-diazobicyclo[2.2.2]octane (Sigma) and analysed by fluorescence microscopy using an Axiophot system (Zeiss, Oberkochen, Germany) processed by using the Metamorph 7.0 software (Universal Imaging, Downingtown, PA).

Injection of zebrafish embryos

Zebrafish (Danio rerio) were bred and maintained in our animal facility under standard conditions. For all microinjection methods, WT embryos obtained by single pair mating of 6–18-month-old male and female AB/TL strain zebrafish were used. Injections were performed at the one-cell stage except when indicated otherwise. Holding and breeding of zebrafish were in accord with the German laws for animal care under a permit obtained from the Regierungspräsidium Freiburg. Embryos were incubated in 0.3 × Danieau’s medium or 1 × Danieau’s with 1% v/v Penicillin (5,000 U ml−1)/Streptomycin (5,000 μg ml−1) solution (Gibco, Life Technologies) at 28.5 °C. Embryos, injected with recombinant proteins mRNA, or vector DNA were staged according to developmental progress of their non-injected littermates. For mRNA synthesis, SP6 mMessage mMachine Kit and T7 mMessage mMachine Ultra Kit (Ambion, Life Technologies) and the complementary DNAs of the following expression constructs in pCS2+ vector (Invitrogen, Life Technologies) were used: pET-28a(+) Afp18 and pET-28a(+) Afp18 NxN, linearized with NotI; pCS2+Afp18G and pCS2+Afp18G NxN linearized with NotI; pCS2+RHOA and pCS2+RHOA Y34F linearized with Acc65I. The original construct pEGFP-N1-Lifeact64 was subcloned into pCS2+ vector and linearized with NotI. The p13-pCS-H2B-mRFP65 construct was linearized with NotI. The pGI-GFP expression construct linearized with NotI was kindly provided by Gudrun Aspöck. We injected 100 pg Lifeact-GFP, 100 pg H2B-mRFP, 50 pg GFP, 50 pg of RHOA or RHOA Y34F, 0.5 pg of Afp18G or Afp18G NxN mRNA constructs per embryo at one-cell stage unless otherwise indicated. Functionality and quality of mRNA was checked by in vitro translation using Transcend Non-radioactive Translation Detection Systems (Promega Corporation, Madison) of the corresponding mRNA, followed by western blotting (Supplementary Fig. 5b). Afp18G activity of in vitro translated protein was additionally validated by an in vitro glycosylation reaction with recombinant RhoA. For mosaic labelling, plasmid vectors of the following constructs were injected in one blastomere at 16-cell stage: pCS2+ RHOA, pEGFP-C1-Afp18G and pEGFP-C1-Afp18G NxN.

Microscopy and imaging acquisition

For overviews of embryos in 0.3 × or 1 × Danieau’s, a MZ APO stereo microscope (Leica, Wetzlar, Germany) with an AxioCam MRc camera and AxioVS40 V4.8.0.0 software (Zeiss, Jena, Germany) or fluorescent stereo microscope (Leica M165 FC and Leica Application Software (Leica, Mannheim, Germany) was used. For wide-field microscopy, an Axio Examiner.D1 (objective. Plan-neofluar 20 × 1.0) and Zen 2012 (blue edition) software was used (Zeiss, Jena, Germany). For confocal microscopy, an Axio Observer.Z1 spinning disc (objective: LD C-Apochromat × 40/1.1 W) and an Axio Imager Z1 (objective Plan-Apochromat × 63/1.2 W) for single-plane images was used. Images were acquired with ZEN 2012 software (Zeiss, Jena, Germany). Embryos were mounted in 0.8% low melting temperature agarose (Biozyme Sieve GP Agarose, Biozym Scientific, Germany) dissolved in 0.3 × Danieau’s or for fixed samples in PBS. Time-lapse movies of z stacks were acquired with the Axio Observer.Z1 spinning disc microscope. The confocal parameters of the time series were: average z-stack depth about 30 μm (2.5 μm per slice) with 3-min intervals for a total of 1 h unless otherwise noted. Time series were analysed and processed with Zen 2012 (blue edition) software. Figure panels were generated using Adobe Photoshop CS4 Extended. When image adjustments were necessary, all images representing control and experimental samples were adjusted in an identical manner by using the Photoshop ‘levels’ tool to spread the intensity values linearly to fill the 256 values of the RGB spectrum. Images show cells or embryos representative for each experimental condition.


Embryos were fixed with 4% paraformaldehyde in PBS for 2 h at room temperature. After washing with PBST (PBS, 0.5% Triton X-100), the embryos were dechorionated manually. Embryos were dehydrated with methanol overnight at −20 °C. Rehydrated embryos were blocked in PBST, 5% goat serum, 1% BSA for 2 h and incubated with primary (anti-GFP and anti-Rho) antibodies in blocking solution overnight. Embryos were washed 6 h with PBST followed by the secondary antibody (anti-chicken Alexa Fluor 488 and anti-rabbit Alexa Fluor 555) incubation in blocking solution. The embryos were finally washed 5 × in PBST before imaging.

Hydrolysis of UDP-sugars by Afp18G

UDP-sugar hydrolysis was measured as described earlier66. Afp18G (100 nM) was incubated with 10 μM UDP-[14C]-sugars in a buffer, containing 50 mM Hepes pH 7.5, 2 mM MgCl2 and 1 mM MnCl2. Total volume was 10 μl. After incubation for 15 min at 30 °C, samples of 800 nl were taken and subjected to PEI (polyethylenimine)-cellulose thin-layer chromatography (Merck, Darmstadt, Germany) with 0.2 mM LiCl as mobile phase to separate the hydrolysed sugar from intact UDP-sugar. The plates were dried and analysed by PhosphorImager analysis. Quantification was carried out with ImageQuant (GE Healthcare).

Glycosylation reaction

Recombinant AfpG (10 nM if not otherwise stated) was incubated with 10 μM UDP-[14C]N-acetylglucosamine in a buffer, containing 50 mM HEPES pH 7.4, 2 mM MgCl2 and 1 mM MnCl2 for 20 min at 30 °C in the presence of recombinant GST-tagged GTP-binding proteins (2 μM) or cell lysate. Total volume was 20 μl. Labelled proteins were analysed by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and phosphorimaging. Uncropped gels and autoradiographs from the corresponding figures of the main text are presented in Supplementary Fig. 6. For quantitative modification, GST-RhoA bound to glutathione-Sepharose beads were modified with Afp18G (10 nM) and UDP-GlcNAc (100 μM). Beads were extensively washed with glycosylation buffer and RhoA eluted by thrombin cleavage in buffer C (10 mM TEA pH 7.5, 150 mM NaCl and 2.5 mM MgCl2). Thrombin was removed by incubation with benzamidine-Sepharose. Complete glycosylation was confirmed by a second in vitro glycosylation reaction. All glycosylation reactions were repeated three times.

GlcNAz labelling

Recombinant RhoA (6 μg), TAB1 (1 μg) or cell lysate (130 μg) was incubated with 4 μM uridine diphosphate N-azidoacetylglucosamine (UDP-GlcNAz) in the presence of Afp18G or Afp18G NxN (each 24 nM) in a buffer containing 10 mM Hepes, pH 7.5, 2 mM MgCl2, 1 mM MnCl2 and 0.1 mg ml−1 BSA for 60 min at 30 °C. Detection of GlcNAz-modified proteins was performed by click chemistry reaction with biotin alkyne according to the manufacturer’s instructions (Click-iT Biotin Protein Analysis Detection Kit, Molecular Probes, Darmstadt, Germany) and western blotting using HRP-coupled streptavidin (dilution 1:10,000, Cell Signaling, Danvers, MA).

Deglycosylation reaction

Recombinant RhoA (6 μg), TAB1 (1 μg) or Rho GTPases of cell lysate (130 μg) were labelled with either radiolabeled UDP-[14C]GlcNAc or UDP-GlcNAz in a glycosylation reaction with Afp18G (24 nM) or human O-glycosyltransferase (OGT, 0.5 μM) as described above. The reaction volume was 20 μl. Subsequently, 0.5 μM recombinant human OGA or Clostridium perfringens CpNagJ were added to the reaction mixture for 60 min at 37 °C. Remaining glycosides were detected by radiography or biotin alkyne click chemistry with western blotting using HRP-coupled streptavidin, respectively.

Mass spectrometry

Glycosylation of RhoA, Rac1 and Cdc42 (5 μg each) was performed with Afp18G (100 nM) in the presence of UDP-GlcNAc (1 mM) for 30 min at 30 °C in glycosylation buffer. After SDS–PAGE, excised gel bands were destained with 30% acetonitrile (ACN), shrunk with 100% ACN and dried in a vacuum concentrator. Subsequently, protein digestion with thermolysin was performed overnight at 37 °C in 0.1 M NH4HCO3 (pH 8). Approximately 0.1 μg of protease per gel band was used. Peptides were extracted from the gel matrix with 5% formic acid and subsequently analysed by LC–MS on a Q-TOF mass spectrometer (Agilent 6520, Agilent Technologies) coupled to a 1200 Agilent nanoflow system via a HPLC-Chip cube electrospray ionization interface. Peptides were separated on a HPLC-Chip with an analytical column of 75 μm i.d. and 150 mm length and a 40-nl trap column, both packed with Zorbax 300SB C-18 (5 μm particle size). Starting with 3% ACN, a linear gradient with 1% per min at a flow rate of 300 nl min−1 was applied. The Q-TOF instrument was operated in the 2-GHz extended dynamic range mode and MS spectra were acquired in the mass-to-charge (m/z) range between 50 and 3,000. For MS–MS analyses, the instrument was operated in the data-dependent acquisition mode. After a survey MS scan (four spectra s−1), a maximum of three multiple charged peptides were consecutively selected for MS–MS experiments (two spectra s−1). Internal mass calibration was applied. Mascot Distiller 2.4.2 was used for raw data processing and for generating peak lists, essentially with standard settings for the Agilent Q-TOF instrument. Mascot Server 2.3 was used for searches in the SwissProt protein database with the following parameters—peptide mass tolerance, 50 p.p.m.; MS–MS mass tolerance, 0.05 Da; enzyme, no specificity; variable modifications, Carbamidomethyl (C), Gln-> pyroGlu (N-term. Q), oxidation (M) and HexNAc (STY).

Effector pull-down assay

The Rho-binding region of Rhotekin (amino acids 1–90) and the CRIB-domain of PAK (amino acids 56–272) were expressed as GST-fusion protein in E. coli BL21 and purified by affinity chromatography with glutathione-Sepharose beads (GE Healthcare). The Rho-binding region of Rho kinase α (ROCKII) was expressed as maltose-binding protein (MBP)-fusion and purified with amylose-resin (New England Biolabs). HeLa or ZF4 cells were treated for 4 h with or without GST-CNF1 (400 ng ml−1) to activate Rho GTPases and a combination of PA (0.5 μg ml−1) and Yersinia Afp18 glucosyltransferase fragments (100 ng ml−1) or C. difficile toxin B (TcdB, 1 ng ml−1). After stimulation of the cells with serum (10% FCS) for 10 min, cells were lysed in ice-cold buffer A (50 mM Tris pH 7.4, 100 mM NaCl, 1% NP-40, 10% glycerol, 2 mM MgCl2 and 1 mM phenylmethanesulfonylfluoride) and cellular debris were removed by centrifugation (3 min, 17,000 g). A fraction of the cleared lysates (50 μg of total protein) was analysed by immunoblotting to detect total amounts of the respective GTPases. The lysates were incubated for 20 min at 4 °C with MBP-ROCKII, GST-Rhotekin or GST-PAK immobilized on beads. The beads were precipitated and washed with buffer A. Finally, the proteins were subjected to SDS–PAGE and transferred onto polyvinylidene difluoride membranes and GTPases detected by using specific antibodies and HRP-linked secondary antibodies. Uncropped western blots from the corresponding figures of the main text are presented in Supplementary Fig. 6.

Mant-GDP- and mant-GppNHp-binding

The measurements were carried out on a LS50B spectrofluorometer from Perkin-Elmer at 37 °C. The amount of nucleotide (GDP/GTP) bound to RhoA was determined by ion-pair reversed-phase liquid chromatography using a C-18 RP column (LiChrosorb 5 μm, 250 × 4 mm) using an Agilent 1100 HPLC system with a calibrated detector system (absorbance of guanine at 252.4 nm). The separation of the nucleotides was performed at ambient temperature with a flow rate of 1 ml min−1 with an isocratic phosphate buffer (50 mM, pH 6.5) containing 10 mM tetra-butylammoniumbromide and 7.5% acetonitrile. For nucleotide exchange experiments, 98.6±1.3% of RhoA was preloaded with GDP. The nucleotide exchange of RhoA was measured over the time by following the increase in fluorescence intensity at λem=444 nm (λex=360 nm) of mant-nucleotides on binding to RhoA. Mant-GDP or mant-GppNHp (each 1 μM) was incubated with RhoA (0.5 μM) in degased buffer C (10 mM TEA, pH 7.5, 150 mM NaCl and 2.5 mM MgCl2). The samples were excited in a cycle of 1 min for 1 s.

Guanine nucleotide exchange reaction measurements

WT RhoA and Afp18G-preglycosylated RhoA (each 0.5 μM) were incubated with mant-GDP or mant-GppNHp (each 1 μM) in degased buffer C at 20 °C in the absence or presence of 100 nM LARG and incubated for the indicated time periods. Fluorescence was measured with a LS50B spectrofluorometer at λem=460 nm (λex=360). Each experiment was repeated at least twice.

Assay for GAP-stimulated GTPase activity

RhoA (3.6 μM) was incubated with Afp18G (170 nM) in the absence (RhoA control) or presence UDP-GlcNAc (330 μM) (RhoA-GlcNAc). Subsequently, RhoA was loaded with [γ-32P]GTP (20 μM) for 5 min at 37 °C in loading buffer (50 mM Tris-HCl pH 7.5, 10 mM EDTA and 2 mM DTT). MgCl2 (25 mM, final concentration) and unlabelled GTP (2 mM, final concentration) were added. GAP-stimulated GTPase activity was measured at 25 °C by the addition of the 30 kDa active fragment of p50RhoGAP (550 nM, final concentration). At the indicated time points, proteins were collected by filtration through wet 0.22 μm nitrocellulose filter discs. The filters were washed three times with ice-cold buffer A (50 mM Tris-HCl, pH 7.5, 50 mM NaCl and 5 mM MgCl2), and protein-bound [γ-32P]GTP was quantified by liquid scintillation counting.

RhoA-GlcNAc crystallization

A truncated version of RhoA covering amino acids 1–181 was expressed from a pGEX-based plasmid as GST-fusion protein. The tag was removed by thrombin cleavage in a buffer containing 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 5 mM MgCl2, 5 mM dithiotreitol and 10% glycerol. After removal of thrombin by benzamidine-sepharose beads, RhoA (15 mg ml−1) was glycosylated by incubation with His-Afp18G (170 nM) in the presence of 1 mM UDP-GlcNAc at 30 °C for 30 min. Quantitative glycosylation was proven by a second glycosylation with Afp18G using radiolabelled UDP-[14C]GlcNAc. After the removal of His-Afp18G by Ni2+ affinity chromatography, RhoA-GlcNAc was purified by size-exclusion chromatography Superdex 200 (10/300) in a buffer containing 10 mM HEPES pH 7.4, 50 mM NaCl and 1 mM MgCl2, concentrated to 7.7 mg ml−1 and crystallized in a 1:1 mixture with reservoir solution (0.1 M sodium acetate, pH 5 and 1.5 M ammonium sulfate). Crystals were obtained at 20 °C after 6 days with the sitting-drop vapour diffusion method and measured after cryoprotection with 20% glycerol in mother liquor.

Structure determination

Diffraction data were collected at 100 K with a Rigaku M007HF X-ray generator and a Saturn 944HG+ CCD detector. The wavelength was 1.54 Å. Data were processed with HKL3000R. The initial phases were calculated by molecular replacement using Molrep from the CCP4 software suite67 with RhoA (PDB code 1pdf) as a search model using the reflections from 50 to 3.5 Å. The structure was further refined by rigid body and iterative restraint refinement with the software Refmac5 (ref. 68) and model building in COOT69. Structural data are summarized in Table 1. The electron density of the GlcNAc moiety, GDP and a sulfate were clearly observed in the unbiased Fo−Fc map, but no Mg2+ ion was found. Electron density of the side chains from amino acid Glu32, Arg128, and Glu142 were poorly defined; therefore, amino acids were modelled as alanines. A crystallographic information file with the refinement restraints of the alpha-GlcNAc-Tyr bond was created in JLigand70. Structure images were prepared using PyMOL (

Statistical analysis

Analysis of variance was performed using GraphPad PRISM. Kruskal–Wallis and Mann–Whitney U-tests were applied. Student’s t-test was applied for pairwise statistical comparison. Fisher’s exact test was applied for statistical analysis of the data set in Fig. 2b, using VassarStats (

Additional information

Accession codes: Atomic coordinates and structure factors for the reported crystal structure are deposited at the RCSB data bank under accession code 5A0F.

How to cite this article: Jank, T. et al. Tyrosine glycosylation of Rho by Yersinia toxin impairs blastomere cell behaviour in zebrafish embryos. Nat. Commun. 6:7807 doi: 10.1038/ncomms8807 (2015).


  1. 1

    Hall, A. Rho GTPases and the actin cytoskeleton. Science 279, 509–514 (1998).

    ADS  CAS  Article  PubMed  Google Scholar 

  2. 2

    Visvikis, O., Maddugoda, M. P. & Lemichez, E. Direct modifications of Rho proteins: deconstructing GTPase regulation. Biol. Cell 102, 377–389 (2010).

    CAS  Article  PubMed  Google Scholar 

  3. 3

    Goody, R. S. & Itzen, A. Modulation of small GTPases by Legionella. Curr. Top. Microbiol. Immunol. 376, 117–133 (2013).

    PubMed  PubMed Central  Google Scholar 

  4. 4

    Aktories, K. Bacterial protein toxins that modify host regulatory GTPases. Nat. Rev. Microbiol. 9, 487–498 (2011).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Lemichez, E. & Aktories, K. Hijacking of Rho GTPases during bacterial infection. Exp. Cell Res. 319, 2329–2336 (2013).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Torraca, V., Masud, S., Spaink, H. P. & Meijer, A. H. Macrophage-pathogen interactions in infectious diseases: new therapeutic insights from the zebrafish host model. Dis. Model. Mech. 7, 785–797 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7

    Jank, T. et al. A bacterial toxin catalyzing tyrosine glycosylation of Rho and deamidation of Gq and Gi proteins. Nat. Struct. Mol. Biol. 20, 1273–1280 (2013).

    CAS  Article  PubMed  Google Scholar 

  8. 8

    Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).

    ADS  CAS  Article  PubMed  Google Scholar 

  9. 9

    Murali, A. & Rajalingam, K. Small Rho GTPases in the control of cell shape and mobility. Cell Mol. Life Sci. 71, 1703–1721 (2014).

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Kardash, E. et al. A role for Rho GTPases and cell-cell adhesion in single-cell motility in vivo. Nat. Cell Biol. 12, 47–53 (2010).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Clay, M. R. & Halloran, M. C. Cadherin 6 promotes neural crest cell detachment via F-actin regulation and influences active Rho distribution during epithelial-to-mesenchymal transition. Development 141, 2506–2515 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12

    Marlow, F., Topczewski, J., Sepich, D. & Solnica-Krezel, L. Zebrafish Rho kinase 2 acts downstream of Wnt11 to mediate cell polarity and effective convergence and extension movements. Curr. Biol. 12, 876–884 (2002).

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Xu, X. et al. Swap70b is required for convergent and extension cell movement during zebrafish gastrulation linking Wnt11 signalling and RhoA effector function. Dev. Biol. 386, 191–203 (2014).

    CAS  Article  PubMed  Google Scholar 

  14. 14

    Zhu, S., Liu, L., Korzh, V., Gong, Z. & Low, B. C. RhoA acts downstream of Wnt5 and Wnt11 to regulate convergence and extension movements by involving effectors Rho kinase and Diaphanous: use of zebrafish as an in vivo model for GTPase signaling. Cell Signal. 18, 359–372 (2006).

    CAS  Article  PubMed  Google Scholar 

  15. 15

    Stoletov, K., Montel, V., Lester, R. D., Gonias, S. L. & Klemke, R. High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc. Natl Acad. Sci. USA 104, 17406–17411 (2007).

    ADS  CAS  Article  PubMed  Google Scholar 

  16. 16

    Salas-Vidal, E., Meijer, A. H., Cheng, X. & Spaink, H. P. Genomic annotation and expression analysis of the zebrafish Rho small GTPase family during development and bacterial infection. Genomics 86, 25–37 (2005).

    CAS  Article  PubMed  Google Scholar 

  17. 17

    Lai, S. L., Chang, C. N., Wang, P. J. & Lee, S. J. Rho mediates cytokinesis and epiboly via ROCK in zebrafish. Mol. Reprod. Dev. 71, 186–196 (2005).

    CAS  Article  PubMed  Google Scholar 

  18. 18

    Shen, M. et al. Discovery of Rho-kinase inhibitors by docking-based virtual screening. Mol. Biosyst. 9, 1511–1521 (2013).

    CAS  Article  PubMed  Google Scholar 

  19. 19

    Rucker, R. R. Redmouth disease of rainbow trout (Salmo gairdneri). Bull. Off Int. Epizoot 65, 825–830 (1966).

    CAS  PubMed  Google Scholar 

  20. 20

    Heymann, J. B. et al. Three-dimensional structure of the toxin-delivery particle antifeeding prophage of Serratia entomophila. J. Biol. Chem. 288, 25276–25284 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21

    Sarris, P. F., Ladoukakis, E. D., Panopoulos, N. J. & Scoulica, E. V. A phage tail-derived element with wide distribution among both prokaryotic domains: a comparative genomic and phylogenetic study. Genome Biol. Evol. 6, 1739–1747 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22

    Yang, G., Dowling, A. J., Gerike, U., ffrench-Constant, R. H. & Waterfield, N. R. Photorhabdus virulence cassettes confer injectable insecticidal activity against the wax moth. J. Bacteriol. 188, 2254–2261 (2006).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23

    Rybakova, D. et al. Role of antifeeding prophage (Afp) protein Afp16 in terminating the length of the Afp tailocin and stabilizing its sheath. Mol. Microbiol. 89, 702–714 (2013).

    CAS  Article  PubMed  Google Scholar 

  24. 24

    Hurst, M. R., Beard, S. S., Jackson, T. A. & Jones, S. M. Isolation and characterization of the Serratia entomophila antifeeding prophage. FEMS Microbiol. Lett. 270, 42–48 (2007).

    CAS  Article  PubMed  Google Scholar 

  25. 25

    Solnica-Krezel, L., Stemple, D. L. & Driever, W. Transparent things: cell fates and cell movements during early embryogenesis of zebrafish. Bioessays 17, 931–939 (1995).

    CAS  Article  PubMed  Google Scholar 

  26. 26

    Davis, J. M. et al. Real-time visualization of mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693–702 (2002).

    CAS  Article  PubMed  Google Scholar 

  27. 27

    Benard, E. L. et al. Infection of zebrafish embryos with intracellular bacterial pathogens. J. Vis. Exp. 61, e3781 (2012).

    Google Scholar 

  28. 28

    Sieger, D., Stein, C., Neifer, D., van der Sar, A. M. & Leptin, M. The role of gamma interferon in innate immunity in the zebrafish embryo. Dis. Model. Mech. 2, 571–581 (2009).

    CAS  Article  PubMed  Google Scholar 

  29. 29

    Jank, T. & Aktories, K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 16, 222–229 (2008).

    CAS  Article  PubMed  Google Scholar 

  30. 30

    Busch, C. et al. A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins. J. Biol. Chem. 273, 19566–19572 (1998).

    CAS  Article  PubMed  Google Scholar 

  31. 31

    Belyi, Y. et al. Legionella pneumophila glucosyltransferase inhibits host elongation factor 1A. Proc. Natl Acad. Sci. USA 103, 16953–16958 (2006).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32

    De, K. S. et al. Yersinia ruckeri, an unusual microorganism isolated from a human wound infection. New Microbes New Infect. 2, 134–135 (2014).

    Article  Google Scholar 

  33. 33

    Driever, W. & Rangini, Z. Characterization of a cell line derived from zebrafish (Brachydanio rerio) embryos. In Vitro Cell Dev. Biol. Anim. 29A, 749–754 (1993).

    CAS  Article  PubMed  Google Scholar 

  34. 34

    Blanke, S. R., Milne, J. C., Benson, E. L. & Collier, R. J. Fused polycationic peptide mediates delivery of diphtheria toxin A chain to the cytosol in the presence of anthrax protective antigen. Proc. Natl Acad. Sci. USA 93, 8437–8442 (1996).

    ADS  CAS  Article  PubMed  Google Scholar 

  35. 35

    Cunningham, C. C. et al. Actin-binding protein requirement for cortical stability and efficient locomotion. Science 255, 325–327 (1992).

    ADS  CAS  Article  PubMed  Google Scholar 

  36. 36

    Salbreux, G., Charras, G. & Paluch, E. Actin cortex mechanics and cellular morphogenesis. Trends Cell Biol. 22, 536–545 (2012).

    CAS  Article  PubMed  Google Scholar 

  37. 37

    Paluch, E. K. & Raz, E. The role and regulation of blebs in cell migration. Curr. Opin. Cell Biol. 25, 582–590 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38

    Charras, G. & Paluch, E. Blebs lead the way: how to migrate without lamellipodia. Nat. Rev. Mol. Cell Biol. 9, 730–736 (2008).

    CAS  Article  PubMed  Google Scholar 

  39. 39

    Sanz-Moreno, V. et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 135, 510–523 (2008).

    CAS  Article  PubMed  Google Scholar 

  40. 40

    Reymond, N. et al. Cdc42 promotes transendothelial migration of cancer cells through beta1 integrin. J. Cell Biol. 199, 653–668 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41

    Wei, Y. et al. Crystal structure of RhoA-GDP and its functional implications. Nat. Struct. Biol. 4, 699–703 (1997).

    CAS  Article  PubMed  Google Scholar 

  42. 42

    Ihara, K. et al. Crystal structure of human RhoA in a dominantly active form complexed with a GTP analogue. J. Biol. Chem. 273, 9656–9666 (1998).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43

    Buettner, F. F., Ashikov, A., Tiemann, B., Lehle, L. & Bakker, H. C. elegans DPY-19 is a C-mannosyltransferase glycosylating thrombospondin repeats. Mol. Cell 50, 295–302 (2013).

    CAS  Article  PubMed  Google Scholar 

  44. 44

    Li, S. et al. Pathogen blocks host death receptor signalling by arginine GlcNAcylation of death domains. Nature 501, 242–246 (2013).

    ADS  CAS  Article  PubMed  Google Scholar 

  45. 45

    Pearson, J. S. et al. A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature 501, 247–251 (2013).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46

    Schmidt, G. et al. Gln63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor 1. Nature 387, 725–729 (1997).

    ADS  CAS  Article  PubMed  Google Scholar 

  47. 47

    Hamm, E. E. & Ballard, J. D. Elucidating the in vivo targets of bacterial toxins. Future Microbiol. 2, 85–92 (2007).

    CAS  Article  PubMed  Google Scholar 

  48. 48

    Fackler, O. T. & Grosse, R. Cell motility through plasma membrane blebbing. J. Cell Biol. 181, 879–884 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49

    Piekny, A., Werner, M. & Glotzer, M. Cytokinesis: welcome to the Rho zone. Trends Cell Biol. 15, 651–658 (2005).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50

    Liu, A. X., Rane, N., Liu, J. P. & Prendergast, G. C. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells. Mol. Cell Biol. 21, 6906–6912 (2001).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  51. 51

    Hakem, A. et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 19, 1974–1979 (2005).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. 52

    Hakeda-Suzuki, S. et al. Rac function and regulation during Drosophila development. Nature 416, 438–442 (2002).

    ADS  CAS  Article  PubMed  Google Scholar 

  53. 53

    Dvorsky, R. & Ahmadian, M. R. Always look on the bright site of Rho: structural implications for a conserved intermolecular interface. EMBO Rep. 5, 1130–1136 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54

    Uezu, A. et al. Modified SH2 domain to phototrap and identify phosphotyrosine proteins from subcellular sites within cells. Proc. Natl Acad. Sci. USA 109, E2929–E2938 (2012).

    CAS  Article  PubMed  Google Scholar 

  55. 55

    Moritz, A. et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci. Signal. 3, ra64 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  56. 56

    Rafikov, R. et al. Lipopolysaccharide-induced lung injury involves the nitration-mediated activation of RhoA. J. Biol. Chem. 289, 4710–4722 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57

    Yarbrough, M. L. et al. AMPylation of Rho GTPases by Vibrio VopS disrupts effector binding and downstream signaling. Science 323, 269–272 (2009).

    CAS  Article  PubMed  Google Scholar 

  58. 58

    Shikuma, N. J. et al. Marine tubeworm metamorphosis induced by arrays of bacterial phage tail-like structures. Science 343, 529–533 (2014).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59

    Russell, A. B. et al. Type VI secretion delivers bacteriolytic effectors to target cells. Nature 475, 343–347 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60

    Russell, A. B. et al. Diverse type VI secretion phospholipases are functionally plastic antibacterial effectors. Nature 496, 508–512 (2013).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  61. 61

    Suarez, G. et al. A type VI secretion system effector protein, VgrG1, from Aeromonas hydrophila that induces host cell toxicity by ADP ribosylation of actin. J. Bacteriol. 192, 155–168 (2010).

    CAS  Article  PubMed  Google Scholar 

  62. 62

    Pukatzki, S., Ma, A. T., Revel, A. T., Sturtevant, D. & Mekalanos, J. J. Type VI secretion system translocates a phage tail spike-like protein into target cells where it cross-links actin. Proc. Natl Acad. Sci. USA 104, 15508–15513 (2007).

    ADS  CAS  Article  PubMed  Google Scholar 

  63. 63

    Just, I., Selzer, J., Hofmann, F. & Aktories, K. in Bacterial toxins—Tools In Cell Biology And Pharmacology ed. Aktories K. 159–168Chapman & Hall (1997).

  64. 64

    Riedl, J. et al. Lifeact: a versatile marker to visualize F-actin. Nat. Methods 5, 605–607 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  65. 65

    Megason, S. G. & Fraser, S. E. Digitizing life at the level of the cell: high-performance laser-scanning microscopy and image analysis for in toto imaging of development. Mech. Dev. 120, 1407–1420 (2003).

    CAS  Article  PubMed  Google Scholar 

  66. 66

    Jank, T., Giesemann, T. & Aktories, K. Clostridium difficile glucosyltransferase toxin B—essential amino acids for substrate-binding. J. Biol. Chem. 282, 35222–35231 (2007).

    CAS  Article  PubMed  Google Scholar 

  67. 67

    Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  68. 68

    Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355–367 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. 69

    Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).

    Article  PubMed  PubMed Central  Google Scholar 

  70. 70

    Lebedev, A. A. et al. JLigand: a graphical tool for the CCP4 template-restraint library. Acta Crystallogr. D Biol. Crystallogr. 68, 431–440 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


We thank Peter Gebhardt for technical assistance. We thank Mohammad Reza Ahmadian (University Düsseldorf, Germany) for plasmid pGEX4T1-LARG, Alfred Wittinghofer (Max Planck Institute of Molecular Physiology, Dortmund, Germany) for pGEX human RhoA(1–181), Sandra Link for pCS2+ Lifeact-GFP and Sabine Götter for expert zebrafish care. We thank Vladimir Borodkin (University of Dundee, UK) for providing UDP-GlcNAz. We thank Alexandra Walter (Department of Pharmaceutical Sciences, University Freiburg, Germany) for technical support on HPLC. We thank the Life Imaging Center (ZBSA, University Freiburg, Germany) for excellent support in image recording and analysis. This study was supported by the Excellence Initiative of the German Federal and State Governments, the Centre for Biological Signalling Studies BIOSS EXC 294, Freiburg Institute for Advanced Studies (to K.A. and W.D.), the German Research Foundation (DFG-SFB850-A1 to W.D. and DFG-SFB746-A17 to K.A. and T.J.), the MRC Programme Grant (M004139 to D.M.F.v.A.) and a Wellcome Trust Senior Research Fellowship (WT087590MA to D.M.F.v.A.).

Author information




T.J. designed the study, performed the experiments, analysed the data and wrote the paper; K.A. designed the study, analysed the data and wrote the paper; S.E. and W.D. performed and analysed the zebrafish injection experiments and wrote the paper; M. Steinemann and C.T. performed experiments, analysed the data; S.W. performed MS analyses; T.J., M. Schimpl, D.M.F.v.A. designed the protein crystallization, performed X-ray analysis and analysed the glyco-RhoA structure; all authors discussed the results and commented on the manuscript.

Corresponding author

Correspondence to Klaus Aktories.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figures and Tables

Supplementary Figures 1-6 and Supplementary Tables 1-2 (PDF 4326 kb)

Supplementary Movie 1

Time lapse movie of blastomeres expressing Afp18G NxN and Afp18G. Embryos were labeled with Lifeact-GFP and H2B-dsRed. Time series of confocal stacks (total depth = 5 ȝm) of the blastoderm were recorded at 2.1 min intervals (total duration = 60 min) upper row shows DIC image series, lower row epifluorescent image series. Asterisk marks an exemplified dividing cell failing in cytokinesis. Animal view, scale bar, 20 μm. (Related to Figure 4a). (MOV 5715 kb)

Supplementary Movie 2

Time lapse movie of blastomere membrane protrusions of Afp18G NxN and Afp18G injected embryos. Embryos were labeled with Lifeact-GFP. Widefield images of the blastoderm were recorded at 10 s intervals (total duration = 5 min). Upper row shows DIC image series, lower row the corresponding epifluorescent image series. Asterisk marks bleb formation, tick shows lamellipodia formation. Animal view, scale bar, 10 μm. (Related to Figure 5). (MOV 5289 kb)

Supplementary Movie 3

Effects of Afp18G on the actin cytoskeleton. Time lapse movie of GFP-actin expressing ZF4 cells intoxicated with recombinant Afp18G NxN and Afp18G in combination with PA as delivery system. (Related to Figure 3c) (MOV 5957 kb)

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jank, T., Eckerle, S., Steinemann, M. et al. Tyrosine glycosylation of Rho by Yersinia toxin impairs blastomere cell behaviour in zebrafish embryos. Nat Commun 6, 7807 (2015).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing